GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (LTS:0QCO) » Definitions » Short Interest

Pharming Group (LTS:0QCO) Short Interest


View and export this data going back to 2007. Start your Free Trial

What is Pharming Group Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Pharming Group's Short Interest

For the Biotechnology subindustry, Pharming Group's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharming Group's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Short Interest distribution charts can be found below:

* The bar in red indicates where Pharming Group's Short Interest falls into.


;
;

Pharming Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (LTS:0QCO) » Definitions » Short Interest
Comparable Companies
XAMS:VVY XAMS:GLPG VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270 SMMT RPRX XKRX:196170 OCSE:GMAB INSM BMRN HKSE:02269 SHSE:603392
Traded in Other Exchanges
PHAR:USA PHGUF:USA PHARM:Netherlands PHGN:Germany
Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Website
https://www.pharming.com
Pharming Group is a biopharmaceutical company. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. In addition, the firm's development pipeline includes KL1333, a potential first-in-disease asset for mitochondrial DNA-driven primary mitochondrial diseases. The company's reportable segments are RUCONEST, which derives maximum revenue, Joenja, U.S., and Europe and the Rest of the World (RoW). Geographically, it derives maximum revenue from the United States.

Pharming Group Headlines

No Headlines